Clinical Trials Logo

Newly Diagnosed Multiple Myeloma clinical trials

View clinical trials related to Newly Diagnosed Multiple Myeloma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04348006 Withdrawn - Clinical trials for Newly Diagnosed Multiple Myeloma

Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients

MM
Start date: March 1, 2020
Phase: Phase 4
Study type: Interventional

Bortezomib considered the standard of care for treating multiple myeloma patients, the aim was to assess the safety and efficacy of newly approved drug (Alvocade ®) in Iraq, in newly diagnosed patients.